MCID: ESP025
MIFTS: 45

Esophagus Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Esophagus Adenocarcinoma

MalaCards integrated aliases for Esophagus Adenocarcinoma:

Name: Esophagus Adenocarcinoma 12 15
Adenocarcinoma of Esophagus 12 44 73
Oesophageal Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4914
MeSH 44 C562730
NCIt 50 C4025
SNOMED-CT 68 276803003
UMLS 73 C0279628

Summaries for Esophagus Adenocarcinoma

Disease Ontology : 12 An esophageal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Esophagus Adenocarcinoma, also known as adenocarcinoma of esophagus, is related to adenocarcinoma and squamous cell carcinoma. An important gene associated with Esophagus Adenocarcinoma is HNF1A-AS1 (HNF1A Antisense RNA 1
Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells.
Dysfunction Pattern: Regulation [up-regulated]), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Menthol and Irinotecan have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and colon, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Related Diseases for Esophagus Adenocarcinoma

Diseases related to Esophagus Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 127)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 30.2 ERBB2 HNF1A-AS1 PIK3CA SMAD4 TP53
2 squamous cell carcinoma 29.7 ERBB2 HNF1A-AS1 PIK3CA SMAD4 TP53
3 esophageal cancer 28.4 ERBB2 MIR21 MYC PIK3CA SMAD4 TP53
4 rare adenocarcinoma of the breast 10.9 PIK3CA TP53
5 adult hepatocellular carcinoma 10.9 PIK3CA TP53
6 gallbladder squamous cell carcinoma 10.9 ERBB2 TP53
7 gastric papillary adenocarcinoma 10.9 ERBB2 TP53
8 malignant spiradenoma 10.9 PIK3CA TP53
9 uterine corpus serous adenocarcinoma 10.9 ERBB2 TP53
10 mutyh-associated polyposis 10.8 SMAD4 TP53
11 vulva basal cell carcinoma 10.8 ERBB2 MYC
12 non-proliferative fibrocystic change of the breast 10.8 ERBB2 TP53
13 pleomorphic adenoma carcinoma 10.8 ERBB2 TP53
14 fallopian tube adenocarcinoma 10.7 ERBB2 TP53
15 uterine body mixed cancer 10.7 ERBB2 TP53
16 glioma susceptibility 1 10.7 ERBB2 TP53
17 anal squamous cell carcinoma 10.7 PIK3CA TP53
18 myasthenic syndrome, congenital, 14 10.7 MYC PIK3CA
19 b cell prolymphocytic leukemia 10.7 MYC TP53
20 oral leukoplakia 10.6 ERBB2 TP53
21 suppression of tumorigenicity 12 10.6 PIK3CA SMAD4 TP53
22 breast squamous cell carcinoma 10.6 ERBB2 PIK3CA TP53
23 bladder squamous cell carcinoma 10.6 ERBB2 PIK3CA TP53
24 ovarian cancer 1 10.6 ERBB2 PIK3CA TP53
25 malignant ovarian surface epithelial-stromal neoplasm 10.6 ERBB2 PIK3CA TP53
26 ovary epithelial cancer 10.6 ERBB2 PIK3CA TP53
27 serous cystadenocarcinoma 10.6 ERBB2 PIK3CA TP53
28 hemimegalencephaly 10.6 MYC PIK3CA
29 estrogen-receptor positive breast cancer 10.6 ERBB2 PIK3CA TP53
30 cystadenocarcinoma 10.6 ERBB2 PIK3CA TP53
31 ovarian serous cystadenocarcinoma 10.6 ERBB2 PIK3CA TP53
32 renal cell carcinoma, papillary, 1 10.6 ERBB2 PIK3CA TP53
33 oral cavity cancer 10.6 ERBB2 PIK3CA TP53
34 megaesophagus 10.6 MYC TP53
35 microglandular adenosis 10.6 ERBB2 TP53
36 uterine corpus cancer 10.6 ERBB2 MYC TP53
37 uterine carcinosarcoma 10.6 ERBB2 PIK3CA TP53
38 bile duct carcinoma 10.6 MYC PIK3CA TP53
39 fallopian tube carcinoma 10.6 ERBB2 MYC TP53
40 cell type cancer 10.5 ERBB2 MYC TP53
41 bladder urothelial carcinoma 10.5 ERBB2 PIK3CA TP53
42 skin melanoma 10.5 ERBB2 PIK3CA TP53
43 esophagus squamous cell carcinoma 10.5 AFAP1-AS1 MIR145
44 adenoid cystic carcinoma 10.5 ERBB2 PIK3CA TP53
45 female reproductive organ cancer 10.3 ERBB2 MYC PIK3CA TP53
46 respiratory system cancer 10.3 ERBB2 MYC PIK3CA TP53
47 breast adenocarcinoma 10.3 ERBB2 MYC PIK3CA TP53
48 suppressor of tumorigenicity 3 10.2 MYC TP53
49 gallbladder cancer 10.2 AFAP1-AS1 ERBB2 PIK3CA TP53
50 cowden disease 10.2 MIR21 PIK3CA SMAD4

Graphical network of the top 20 diseases related to Esophagus Adenocarcinoma:



Diseases related to Esophagus Adenocarcinoma

Symptoms & Phenotypes for Esophagus Adenocarcinoma

MGI Mouse Phenotypes related to Esophagus Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.43 ATP4A ERBB2 MYC SMAD4 TP53 ATP12A
2 endocrine/exocrine gland MP:0005379 9.17 ATP4A CDO1 ERBB2 MYC PIK3CA SMAD4

Drugs & Therapeutics for Esophagus Adenocarcinoma

Drugs for Esophagus Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 181)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4 2216-51-5 16666
2
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
3
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 61825-94-3 5310940 9887054 43805 6857599
4
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
5
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68538-85-2
6
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
8
Camptothecin Experimental Phase 4,Phase 2,Phase 1 7689-03-4
9 topoisomerase I inhibitors Phase 4,Phase 2,Phase 1
10 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
11 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
12 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
13 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
14 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
15 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Antidotes Phase 4,Phase 3,Phase 2,Phase 1
17 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Liver Extracts Phase 4,Phase 2,Phase 1
19 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
22 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
23 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
24 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
25
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 154361-50-9 60953
26
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
27
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
28
Esomeprazole Approved, Investigational Phase 3 161796-78-7, 119141-88-7 4594 9579578
29
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
30
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
31
Cetuximab Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 205923-56-4 56842117 2333
32
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
33
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
34
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
35
Trioxsalen Approved Phase 3,Phase 2 3902-71-4 5585
36
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
37
Ranitidine Approved Phase 3 66357-59-3, 66357-35-5 3001055
38
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
39
Trastuzumab Approved, Investigational Phase 3,Phase 2,Phase 1 180288-69-1 9903
40
Ondansetron Approved Phase 3 99614-02-5 4595
41 Analgesics Phase 3,Phase 2,Phase 1
42 Fibrinolytic Agents Phase 3
43 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
44 Gastrointestinal Agents Phase 3
45 Cyclooxygenase Inhibitors Phase 3,Phase 2
46 Analgesics, Non-Narcotic Phase 3,Phase 2,Phase 1
47 Antacids Phase 3
48 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
49 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 270)
# Name Status NCT ID Phase Drugs
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
3 Combination Chemotherapy in Treating Patients With Esophageal Cancer Unknown status NCT00041262 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil
4 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Unknown status NCT00357682 Phase 3 Esomeprazole;Esomeprazole;Aspirin
5 Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002884 Phase 3 chemotherapy;cisplatin;fluorouracil
6 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002883 Phase 3 cisplatin;fluorouracil
7 Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer Unknown status NCT00509561 Phase 2, Phase 3 capecitabine;cisplatin
8 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Unknown status NCT00052910 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil;leucovorin calcium
9 Confocal Endomicroscopy for Barrett's Esophagus Completed NCT00487695 Phase 3
10 Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer Completed NCT00047112 Phase 3 cisplatin;fluorouracil
11 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00002631 Phase 3 chemotherapy;cisplatin;fluorouracil
12 Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00003118 Phase 3 cisplatin;fluorouracil
13 Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer Completed NCT00020787 Phase 3 cisplatin;fluorouracil
14 Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer Completed NCT00861094 Phase 2, Phase 3 cisplatin;5-FU;oxaliplatin;Folinic Acid
15 Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy Completed NCT01243398 Phase 3
16 Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer Completed NCT00978549 Phase 3 docetaxel;steroid therapy
17 Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus Recruiting NCT02509286 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
18 NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) Recruiting NCT01726452 Phase 3 Epirubicin;Cisplatin;5 Flourouracil/ Capecitabine;Paclitaxel;Carboplatin
19 Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction Recruiting NCT01523015 Phase 2, Phase 3
20 STRETTA ,Radio Frequency Ablation (RFA) v/s Sham Therapy for the Treatment of Refractory GERD Recruiting NCT02935881 Phase 3
21 A Randomized, Controlled, Multicenter Study to Compare Preoperative Radiochemotherapy With Preoperative Chemotherapy in Patients With Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Recruiting NCT03013010 Phase 3 Tegafur-Gimeracil-Oteracil Potassium;Oxaliplatin
22 Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Recruiting NCT02628665 Phase 3 photosensitizer(photofrin)
23 Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Active, not recruiting NCT01196390 Phase 3 Carboplatin;Paclitaxel
24 Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery Active, not recruiting NCT01107639 Phase 3 cisplatin;docetaxel
25 Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma Unknown status NCT00964080 Phase 1, Phase 2 MBP-426/Leucovorin/5-FU
26 The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma Unknown status NCT00674167 Phase 2 Docetaxel;Cisplatin;Capecitabine
27 Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach Unknown status NCT00601705 Phase 2 cisplatin;epirubicin hydrochloride;fluorouracil;oxaliplatin
28 Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus Unknown status NCT00903136 Phase 1, Phase 2
29 Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus Unknown status NCT00003326 Phase 2 paclitaxel
30 Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer Unknown status NCT00006472 Phase 2 carboplatin;fluorouracil;paclitaxel
31 Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus Unknown status NCT00005607 Phase 2 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
32 Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer Unknown status NCT00004236 Phase 2 pegylated liposomal doxorubicin hydrochloride
33 Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery Unknown status NCT00005876 Phase 2 rubitecan
34 Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma Completed NCT00220103 Phase 2 epirubicin, capecitabine, cisplatin
35 Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma Completed NCT00583674 Phase 2 AMG 386 placebo;AMG 386 10mg/kg;AMG 386 3mg/kg;Cisplatin;Capecitabine;Cisplatin;Capecitabine;Cisplatin;Capecitabine
36 Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus Completed NCT00259987 Phase 2 Lapatinib (GW572016) oral tablets
37 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction Completed NCT00077545 Phase 2 triapine;cisplatin
38 Phase II Study of Irinotecan and Panitumumab Completed NCT00836277 Phase 2 Panitumumab;Irinotecan
39 Irinotecan in Treating Patients With Esophageal or Stomach Cancer Completed NCT00003748 Phase 2 irinotecan hydrochloride
40 Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia Completed NCT00591123 Phase 2 FOLFOX and Erlotinib
41 Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer Completed NCT00354679 Phase 2 cisplatin;irinotecan hydrochloride
42 Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction Completed NCT00891878 Phase 2 capecitabine;sunitinib malate
43 Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus Completed NCT00066716 Phase 2 carboplatin;celecoxib;paclitaxel
44 Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach Completed NCT00020761 Phase 2 irinotecan hydrochloride;paclitaxel
45 Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer Completed NCT00985192 Phase 2 everolimus
46 Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach Completed NCT00003237 Phase 2 cisplatin;paclitaxel
47 Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Completed NCT00938470 Phase 2 capecitabine;docetaxel;fluorouracil;oxaliplatin
48 Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer Completed NCT00040859 Phase 2 capecitabine;oxaliplatin
49 Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer Completed NCT00033657 Phase 2 cisplatin;irinotecan hydrochloride;paclitaxel
50 Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer Completed NCT00165490 Phase 2 Cetuximab;Cisplatin;Irinotecan

Search NIH Clinical Center for Esophagus Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma of esophagus

Genetic Tests for Esophagus Adenocarcinoma

Anatomical Context for Esophagus Adenocarcinoma

MalaCards organs/tissues related to Esophagus Adenocarcinoma:

41
Testes, Liver, Colon, Lymph Node, Bone

Publications for Esophagus Adenocarcinoma

Articles related to Esophagus Adenocarcinoma:

(show all 12)
# Title Authors Year
1
C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis. ( 27636117 )
2017
2
Preliminary evaluation for Bit1 as a potential biomarker for squamous cell carcinoma and adenocarcinoma of esophagus. ( 28488526 )
2017
3
The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma. ( 28184414 )
2017
4
Epigenetic regulation on the gene expression signature in esophagus adenocarcinoma. ( 28049580 )
2016
5
In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma. ( 24708360 )
2014
6
Esophagus adenocarcinoma in a young patient with celiac disease; Is celiac disease a predisposing factor for esophagus adenocarcinoma as well as squamous cell carcinoma? ( 26185881 )
2014
7
Increase of epidermal growth factor receptor expression in progression of GERD, Barrett, and adenocarcinoma of esophagus. ( 22875307 )
2013
8
Comparative evaluation of serum C-reactive protein (CRP) levels in the different histological subtypes of esophageal cancer (squamous cell carcinoma and adenocarcinoma of esophagus). ( 22467322 )
2012
9
Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis. ( 21166737 )
2010
10
Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. ( 17236199 )
2007
11
Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. ( 16985029 )
2006
12
Meningeal carcinomatosis in patient with esophagus adenocarcinoma. ( 9105327 )
1997

Variations for Esophagus Adenocarcinoma

Expression for Esophagus Adenocarcinoma

Search GEO for disease gene expression data for Esophagus Adenocarcinoma.

Pathways for Esophagus Adenocarcinoma

Pathways related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.7 ERBB2 MYC PIK3CA SMAD4 TP53
2 12.64 ERBB2 MYC PIK3CA SMAD4 TP53
3
Show member pathways
12.54 ERBB2 MYC PIK3CA SMAD4 TP53
4
Show member pathways
12.44 ERBB2 MYC PIK3CA TP53
5
Show member pathways
12.42 MYC PIK3CA SMAD4 TP53
6
Show member pathways
12.33 ERBB2 MYC PIK3CA TP53
7 12.27 MYC PIK3CA SMAD4 TP53
8
Show member pathways
12.25 ERBB2 MYC PIK3CA SMAD4 TP53
9 12.04 MYC PIK3CA TP53
10 12.02 MYC SMAD4 TP53
11 12.02 ERBB2 MIR21 MYC PIK3CA TP53
12
Show member pathways
12.01 ERBB2 MYC PIK3CA
13 11.97 ERBB2 MYC PIK3CA TP53
14 11.96 MYC PIK3CA SMAD4
15 11.93 MYC SMAD4 TP53
16
Show member pathways
11.9 MYC PIK3CA TP53
17
Show member pathways
11.89 ERBB2 PIK3CA TP53
18 11.85 MYC PIK3CA TP53
19
Show member pathways
11.82 MYC PIK3CA SMAD4
20 11.74 MYC PIK3CA TP53
21 11.7 ERBB2 MIR143 MIR145 MIR21 MIR215 MYC
22 11.66 MYC SMAD4 TP53
23 11.59 ERBB2 MYC TP53
24 11.58 ERBB2 PIK3CA TP53
25 11.46 ERBB2 MYC SMAD4
26 11.41 ERBB2 MYC PIK3CA SMAD4 TP53
27 11.38 ERBB2 MYC PIK3CA TP53
28 11.34 MYC SMAD4 TP53
29 11.31 MIR145 MYC TP53
30 11.27 ERBB2 MYC PIK3CA TP53
31 11.2 MYC SMAD4 TP53
32 10.99 MYC TP53
33
Show member pathways
10.98 MYC TP53

GO Terms for Esophagus Adenocarcinoma

Biological processes related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.84 ERBB2 MIR21 MYC TP53
2 cell proliferation GO:0008283 9.81 ERBB2 MYC SMAD4 TP53
3 negative regulation of angiogenesis GO:0016525 9.65 MIR143 MIR145 MIR21
4 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.55 MIR143 MIR21
5 regulation of smooth muscle contraction GO:0006940 9.52 MIR143 MIR145
6 cellular sodium ion homeostasis GO:0006883 9.49 ATP12A ATP4A
7 cellular potassium ion homeostasis GO:0030007 9.46 ATP12A ATP4A
8 positive regulation of protein kinase B signaling GO:0051897 9.46 ERBB2 MIR143 MIR21 PIK3CA
9 sodium ion export across plasma membrane GO:0036376 9.43 ATP12A ATP4A
10 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.4 ATP12A ATP4A
11 angiotensin-activated signaling pathway GO:0038166 9.37 MIR143 MIR145
12 aorta smooth muscle tissue morphogenesis GO:0060414 9.32 MIR143 MIR145
13 regulation of phenotypic switching GO:1900239 9.26 MIR143 MIR145
14 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 8.96 MIR143 MIR145
15 negative regulation of cardiac muscle hypertrophy GO:0010614 8.8 MIR145 MIR21 SMAD4

Molecular functions related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP12A ATP4A
2 potassium:proton exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A

Sources for Esophagus Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....